GLP‑1 suicide study

A new *Molecular Psychiatry* study found no increased risk of suicide or suicide attempts among people starting glucagon-like peptide-1 drugs, the class that includes semaglutide. (nature.com) These medicines mimic a gut hormone that helps control blood sugar and appetite, and some are prescribed for obesity as well as type 2 diabetes. The new paper, published April 18, 2026, compared 83,464 new GLP-1 users with 78,366 users of sodium-glucose cotransporter-2 inhibitors and 108,322 GLP-1 users with 55,411 users of dipeptidyl peptidase-4 inhibitors. (nature.com) In those cohort analyses, GLP-1 users had a hazard ratio of 0.93 versus sodium-glucose cotransporter-2 drugs and 0.58 versus dipeptidyl peptidase-4 drugs for suicide or suicide attempts. In a second design that compared patients with themselves before and after starting treatment, the study also did not find an increased incidence after GLP-1 initiation. (nature.com) The question has been under review since 2023, after regulators in Europe and the United States examined reports of suicidal thoughts and self-injury in people taking these medicines. The European Medicines Agency said on April 12, 2024, that available evidence did not support a causal association and did not warrant a label update. (ema.europa.eu) The U.S. Food and Drug Administration said its preliminary evaluation likewise did not suggest a causal link, but said it could not definitively rule out a small risk because the number of events was low. The agency said it was continuing reviews that include a meta-analysis of trials and postmarketing data in the Sentinel System. (fda.gov) The new paper matters in part because GLP-1 drugs now reach patients who often have overlapping psychiatric risks, including people with obesity, diabetes and prior mental health treatment. The authors wrote that spontaneous case reports had prompted concern but called the broader investigations inconclusive before this analysis. (nature.com) The study did not prove the drugs protect against suicide risk, even though some estimates were lower in GLP-1 users than in comparison groups. Observational studies can miss differences between patients that are hard to measure, and the FDA said rare harms can be difficult to detect when event counts are small. (nature.com) (fda.gov) Wegovy’s U.S. prescribing information still tells clinicians to monitor for depression, suicidal thoughts or behavior, and unusual mood changes, reflecting caution around weight-management drugs more broadly. The label also says patients should stop Wegovy if those symptoms develop. (accessdata.fda.gov) So the picture on April 19, 2026 is narrower than the early alarm: regulators have not found evidence of a causal link, and this large new study did not find an increased rate either. Doctors and patients are still being told to watch for mood changes while the FDA finishes its review. (nature.com) (fda.gov)